Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx) -- Ignore unavailable to you. Want to Upgrade?

To: estatemakr who wrote (80)	5/16/2007 10:51:12 PM
From: Keith Feral	Read Replies (1) \| Respond to of 418

I think that Cofactor wipes out the anemia market for post chemo. Look at the safety results from the R & R slideshow on the website. ANX has already defined the epogen market as the bone marrow support drug for anemia. Bolus injections of intravenous folate increases the efficacy of 5Fu to shut down cancer cell replication and it recovers healthy cells from anemia and all other side effects. It is a disruptive technology, IMO.